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Abstract
Background: To assess the performance of BED-CEIA (BED) and AxSYM Avidity Index (Ax-AI) assays in estimating HIV
incidence among female sex workers (FSW) in Kigali, Rwanda.
Methodology and Findings: Eight hundred FSW of unknown HIV status were HIV tested; HIV-positive women had BED and
Ax-AI testing at baseline and $12 months later to estimate assay false-recent rates (FRR). STARHS-based HIV incidence was
estimated using the McWalter/Welte formula, and adjusted with locally derived FRR and CD4 results. HIV incidence and local
assay window periods were estimated from a prospective cohort of FSW. At baseline, 190 HIV-positive women were BED
and Ax-AI tested; 23 were classified as recent infection (RI). Assay FRR with 95% confidence intervals were: 3.6% (1.2–8.1)
(BED); 10.6% (6.1–17.0) (Ax-AI); and 2.1% (0.4–6.1) (BED/Ax-AI combined). After FRR-adjustment, incidence estimates by BED,
Ax-AI, and BED/Ax-AI were: 5.5/100 person-years (95% CI 2.2–8.7); 7.7 (3.2–12.3); and 4.4 (1.4–7.3). After CD4-adjustment,
BED, Ax-AI, and BED/Ax-AI incidence estimates were: 5.6 (2.6–8.6); 9.7 (5.0–14.4); and 4.7 (2.0–7.5). HIV incidence rates in the
first and second 6 months of the cohort were 4.6 (1.6–7.7) and 2.2 (0.1–4.4).
Conclusions: Adjusted incidence estimates by BED/Ax-AI combined were similar to incidence in the first 6 months of the
cohort. Furthermore, false-recent rate on the combined BED/Ax-AI algorithm was low and substantially lower than for either
assay alone. Improved assay specificity with time since seroconversion suggests that specificity would be higher in
population-based testing where more individuals have long-term infection.
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Introduction
The Serologic Testing Algorithm for Recent HIV Seroconver-
sion (STARHS) offers a promising alternative to prospective
measurement of HIV incidence, particularly in developing
countries where incidence rates may be high but are infrequently
measured owing to limited resources[1–4]. Two main STARHS
assays are the BED capture enzyme immunoassay (BED)[5] and
AxSYM Avidity Index method (Ax–AI)[6]. These and other
STARHS assays exploit biologic properties of early HIV infection,
such as development of HIV antibodies, to distinguish recent from
long-term infections in cross-sectional samples of individuals
testing HIV positive.
Studies conducted in a range of populations and settings,
however, reveal the tendency of STARHS assays, including the
BED and Ax-AI, to misclassify certain individuals with long-term
HIV infection as recently infected, thus inflating HIV incidence
estimates relative to prospective cohort rates[5,7–11]. A number of
strategies have been proposed for correcting assay misclassifica-
tion, including statistical adjustment, assessment of CD4 count and
antiretroviral therapy (ART) status among individuals tested in
order to remove those with probable long-term infection (LTI)
from ‘‘recent infection’’ (RI) classification by the assays prior to
calculation of incidence, and use of a dual testing algorithm in
which a second, different STARHS assay confirms the classifica-
tion on an initial assay[8,9,12–17]. In addition, individuals who
test HIV-positive in a cross-sectional survey can be followed in a
‘‘long-term infection cohort’’ with repeat STARHS testing $12
months later, in order to calculate assay false-recent rates (FRR);
incidence estimates can then be adjusted downward by applying
the FRR to available statistical formulae[8,9,18].
We applied the BED and Ax-AI assays in a cross-sectional survey
andtopost-seroconversionpanelspecimensfromaprospectiveHIV
seroconversion study among female sex workers (FSW) at Projet
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ofsamples testingRI;concordancebetween BED andAx-AIresults;
frequency and factors associated with false-recent classifications by
the assays; estimated mean window periods for the assays based on
data from cohort seroconverters; estimated HIV incidence in the
prospective cohort; and unadjusted and adjusted STARHS-based
incidence estimates for the cross-sectional sample.
Materials and Methods
Eight hundred FSW 18 years and older were HIV tested in a
cross-sectional survey. All women provided written informed
consent prior to study participation. Women who tested HIV
positive during the survey were further tested by the BED and Ax-
AI assays, and then asked to return to the study clinic at least 12
months later for repeat testing by both assays. HIV-negative, non-
pregnant women were eligible to enroll in a prospective HIV
seroconversion cohort. Cohort participants (N=397) returned for
quarterly follow-up visits for one year and then for a single visit
during the second year of follow-up.
HIV testing was by First Response Rapid Test (Premier Medical
Corporation, India) and Uni-Gold Rapid Test (Trinity Biotech
Plc, Ireland), with Capillus HIV-1/HIV-2 Rapid Test (Trinity
Biotech Plc, Ireland) as the tie-breaker. Rapid test-positive results
were confirmed by Murex HIV Ag/Ab Combination ELISA
(Abbott Laboratories, Germany), and tested by CD4 cytometry.
Rapid test-negative specimens were pooled for testing by HIV-1
RNA PCR to identify acute HIV infections (COBAS TaqMan,
Roche Molecular Systems, Inc., USA).
Specimens from participants testing HIV positive in the cross-
sectional survey and cohort were tested with the BED and Ax-AI
assays. The BED assay measures the ratio of HIV-specific
immunoglobulin (IgG) antibody to total antibody; a low
proportion indicates infection within the past 155 days (i.e., RI)
(95% confidence interval [CI]: 146–165)) [2,5]. BED testing was
performed onsite following the manufacturer’s package insert
(CalypteH Biomedical Corporation, Oregon, US)[19]. The Ax-AI
method measures the ‘‘avidity’’—or strength—of the HIV
antibody-antigen bond; avidity is weak among individuals infected
during the past 180 days (i.e., RI)[6,20]. Avidity testing was
performed by the Pediatric HIV Research Unit in South Africa
using the AxSYM HIV-1/2gO ELISA (Abbott, USA), and
following procedures described elsewhere[6,20].
Women who tested HIV positive were given CD4 results and
referred for HIV care and evaluation for treatment eligibility, as
well as psychosocial services. BED and Ax-AI results were not
given to participants, as the assays are designed for research
purposes only[21]. The National Ethics Committee and the
National AIDS Control Commission (CNLS) in Rwanda, and the
Columbia University Medical Center Institutional Review Board
in the United States, approved the study.
Statistical methods
Prospective cohort sample. The estimated cohort HIV
incidence rate and 95% CI were calculated using standard
incidence formulae, assuming a Poisson distribution. HIV
infection was assumed to have occurred at the midpoint between
the last negative HIV test and first positive HIV test.
We estimated study sample-specific mean window periods for
the BED and Ax-AI assays, and combined BED/Ax-AI algorithm.
While rigorous statistical methods, such as mixed effects regression
or survival analysis techniques, are the preferred method for
deriving mean assay window periods (see e.g., [22]), such methods
require substantially larger sample sizes than were available for
this analysis. Instead, we used an approximate method to estimate
assay window periods: we observed in the pattern of antibody
kinetics the point at which each subject crossed the assay cutoff
(0.8 for BED, 0.85 for Ax-AI (Ax-AI cutoff based on personal
communication with B. Suligoi)), and then averaged the values across
subjects to obtain the mean assay window period. To estimate the
window period for the combined BED/Ax-AI algorithm, we took
the value of the earlier of the two assay threshold crossings (BED
or Ax-AI) for each individual, and then averaged across
individuals. For all window period calculations, we excluded
seroconverters who self-reported initiating ART after HIV
diagnosis, individuals lacking additional serial assay results from
post-seroconversion visits, and those who did not reach the
threshold of either assay during follow-up testing. Standard errors
(SE) were calculated around window period estimates using
standard spreadsheet software (Microsoft Excel, 2003).
Cross-sectional survey sample. In the cross-sectional
sample, we calculated the proportion of HIV-infected
participants classified as RI and LTI by each assay, as well as
the proportion with concordant and discordant results on the two
assays. A Kappa coefficient with 95% CI was calculated to
measure agreement between BED and Ax-AI classifications.
HIV-1 incidence estimates and 95% CI based on the BED and
Ax-AI assay results (with BED OD-n#0.80 and Ax-AI#0.85
indicating recent infection) were calculated using the formula, and
accompanying spreadsheet (available at: http://www.sacema.
com/page/assay-based-incidence-estimation; accessed July 8,
2010), provided by McWalter and Welter[23]. Inputs in the
formula include the number of positive individuals in the sample,
the number of recent infections, the assay window period (sample-
specific estimates), and the number of HIV-negative individuals
tested. Incidence estimates are expressed as an incidence rate
(number of new HIV infections per 100 person-years), and
confidence intervals are calculated using a delta method
approximation. Incidence estimates were adjusted with CD4
count data, by excluding individuals with probable long-term
infection (based on CD4,200) from recent infection classifications
for incidence estimate calculations (these individuals were also
excluded from FRR calculations). Further, a separate set of
adjusted incidence estimates was generated by adjusting estimates
with study-specific FRR for the BED and Ax-AI assays, and
combined BED/Ax-AI algorithm. False-recent rate was defined as
the proportion of ART-naı ¨ve, HIV-infected cross-sectional survey
participants with known long-term infection and CD4 count $200
cells/ml who were classified by the BED and/or Ax-AI assay as
having recent infection upon repeat testing $12 months later[8,9].
All statistical analyses were performed using SAS version 9.2
(SAS Institute, Inc., Cary, NC).
Results
Assay results among prospective seroconverters
Nineteen individuals HIV seroconverted during the prospective
cohort study, generating a total of 52 samples (19 from the
seroconversion visit, and 33 post-seroconversion samples). The
duration between seroconverters’ last negative and first positive
HIV test ranged from 83 to 406 days (mean: 204 days; median: 93
days). Among 16 of 19 seroconverters with CD4 data available
within 3 months of the seroconversion visit, median CD4 count
was 549 cells/ml (range: 287–1218).
Figures 1a–b display BED OD-n values and Ax-AI scores,
respectively, over time since HIV seroconversion among prospec-
tive cohort seroconverters (N=11) with BED/Ax-AI results for
post-seroconversion study visits. Among these 11 participants, 6
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follow-up, and 7 saw their Ax-AI result cross the cutoff. Using data
from these participants whose infection status changed from RI to
LTI during follow-up, and excluding data from 2 seroconverters
who reported initiating ART since their HIV diagnosis, the
estimated mean window periods for BED and Ax-AI were
approximately 330 (SE 84.1) and 310 (SE 69.9) days, respectively.
The estimated window period for the combined BED/Ax-AI
algorithm was 267 days (SE 64.8).
Assay classifications in the cross-sectional sample
A total of 192 women tested HIV positive in the cross-sectional
survey(noacute HIVinfectionswere identified byPCR). Asnone of
the women knew their positive HIV serostatus prior to testing, all
participants were ART-naı ¨ve at the time of the survey. Among
HIV-positive participants, 190 were tested by BED and Ax-AI
(Fig. 2): 36 (19%) were classified as RI by BED, and 56 (30%) as RI
by Ax-AI; 23 (12%) were classified as RI by both assays; 121 (64%)
were classified as LTI by both assays; and 46 (24%) were classified
Figure 1. STARHS assay results over time among participants with incident HIV in prospective cohort (N=11).
doi:10.1371/journal.pone.0018402.g001
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concordant for 76% of cross-sectional sample specimens, yielding a
Kappascoreof0.35(95%CI:0.20,0.50).TheSpearmancoefficient
for correlation between BED OD-n and Ax-AI results was 0.24.
False-recent rates
Among the 190 participants with STARHS results from the
survey, 141 (74%) returned for repeat testing by BED and Ax-AI
$12 months later (median 623 days, range: 432–861). Upon
repeat testing, 80% (113/141) of women were correctly classified
as having LTI by both assays. However, 9 women were falsely
classified by BED as RI; 23 women were falsely classified by Ax-AI
as RI; and 4 women were falsely classified by both assays as RI.
Four of the 9 participants with BED-false recent results (44%), 8 of
the 23 participants with Ax-AI-false recent results (35%), and 1 of
the 4 participants with false recent results on the BED/Ax-AI
algorithm (33%), reported taking ART since their HIV diagnosis.
After excluding ART-positive individuals, FRR for the BED and
Ax-AI were 3.6% (95% CI: 1.2–8.1) and 10.6% (95% CI: 6.1–
17.0), respectively. The FRR for the combined BED/Ax-AI
algorithm was 2.1% (95% CI: 0.4–6.1).
Characteristics of individuals testing false-recent on
assays
There was no significant association between testing false-recent
on STARHS $12 months after HIV diagnosis and marital status,
duration between baselineandrepeatSTARHS tests,years working
as a sex worker, or recent AIDS-like symptom (Table 1). However,
there was a borderline significant association between older age and
higher likelihood of testing false-recent on the Ax-AI assay
(P=0.06). Furthermore, participants with a false-recent result on
the Ax-AI assay had a significantly higher median baseline CD4
countthanthosecorrectlyclassifiedbyAx-AI(590vs.444cells/ml,P
,0.01). Median baseline CD4 cell count did not differ between
participants falsely and correctly classified by the BED assay (447 vs.
461 cells/ml, P=0.77). Moreover, on both assays, participants with
a false-recent test result had been HIV tested more frequently in
their lifetimes compared with participants who were correctly
classified as LTI by the assays (BED P=0.01, Ax-AI P=0.02).
Finally, on both assays, testing false-recent was significantly
associated with having been classified as RI by the assay during
the cross-sectional survey (BED P,0.0001, Ax-AI P,0.0001).
Unadjusted and adjusted STARHS incidence rate
estimates
Unadjusted HIV incidence estimates based on the BED, Ax-AI,
and combined BED/Ax-AI algorithm were: 6.5 infections per 100
person-years (PY) (95% CI: 3.2–9.9), 10.8 per 100 PY (95% CI:
5.6–16.0), and 5.2 per 100 PY (95% CI: 2.2–8.1), respectively
(Table 2). Adjustment of assay-based incidence estimates with their
corresponding FRR reduced the BED, Ax-AI, and combined
BED/Ax-AI estimates to: 5.5/100 PY (95% CI: 2.2–8.7); 7.7/100
PY (95% CI: 3.2–12.3); and 4.4/100 PY (1.4–7.3), respectively.
Exclusion of individuals with CD4 count ,200 cells/ml from RI
classification (without adjustment by FRR) reduced the BED, Ax-
AI, and combined BED/Ax-AI estimates to: 5.6/100 PY (95% CI:
2.6–8.6); 9.7/100 PY (95% CI: 5.0–14.4); and 4.7/100 PY (95%
CI: 2.0–7.5), respectively.
Figure 2. Correlation of results on BED-CEIA and AxSYM Avidity Index for recent HIV infection, Cross-sectional sample (N=190).
doi:10.1371/journal.pone.0018402.g002
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estimated cohort incidence rate
In the prospective cohort sample, the estimated 12-month HIV
incidence rate was 3.5 infections per 100 PY (95% CI: 1.6–5.4).
However, HIV incidence showed a non-significant downward
trend over time, with rates of 4.6/100 PY (95% CI: 1.6–7.7) and
2.2/100 PY (95% CI: 0.1–4.4) in the first and second 6 months of
the cohort, respectively. Compared with the highest cohort
incidence rate (from the first 6 months of the cohort), all
STARHS-based incidence estimates for the cross-sectional sample
fell within the confidence bounds of the estimated prospective
cohort rate, except for the unadjusted Ax-AI estimate and the
CD4-adjusted Ax-AI estimate (Fig. 3). The FRR-adjusted Ax-AI
estimate fell nearly within the CI of the prospective rate.
Discussion
In this investigation, incidence estimates based on cross-
sectional data were affected by misclassification by the BED and
Ax-AI assays. The unadjusted BED (6.5/100 PY) and Ax-AI
(10.8/100 PY) incidence estimates were both substantially higher
than our estimated prospective cohort 12-month incidence rate of
3.5/100 PY (95% CI: 1.6–5.4). Even after adjustment for poor
specificity with CD4 data or sample-specific FRR, most assay-
based estimates remained substantially higher than the overall
estimated incidence rate for the prospective cohort. However,
comparison with the incidence rate for the first 6 months of the
cohort showed good correspondence with most STARHS-based
estimates, particularly those for the combined BED/Ax-AI
algorithm (both unadjusted and adjusted).
Comparisons between incidence estimates derived from the
cross-sectional and prospective samples may be fraught for several
reasons. First, by definition, cross-sectional and prospective
incidence rates are estimated at different time points (over some
time prior to baseline and during the months following baseline,
respectively). Second, limited statistical power, as in the case of this
analysis, will make meaningful comparisons between estimates
difficult. Third, CD4- and FRR-adjustment strategies may not
have fully corrected for misclassification in the cross-sectional
sample, thereby leaving residual bias in the BED and Ax-AI
incidence estimates. Fourth, selection bias may have caused the
estimates to diverge, for example if there were differences in risk
Table 1. Characteristics of cross-sectional survey participants with long-term HIV infection by repeat STARHS test result $12
months after HIV diagnosis (N=141).
Characteristic BED-CEIA Assay Avidity Index method
False-recent
result (n=9)
Correctly
classified as
LTI (n=132) P value
1
False-recent
result (n=23)
Correctly
classified as
LTI (n=118) P value
1
Median age in years (IQR) 26.0 (13) 27.0 (9) 0.75 33.0 (15) 27.0 (8) 0.29
Age groups, %:
18–20 45 31 35 31
21–24 11 29 0.41 9 32 0.06
25–29 11 22 21 21
30–34 33 18 35 16
Current breastfeeding, % 33 21 0.40 26 21 0.59
Marital status – Divorced/separated, % 22 12 0.32 13 13 1.0
Marital status – Never married, % 56 66 0.72 61 66 0.64
Marital status – Widowed, % 22 22 1.0 26 21 0.59
Have HIV positive sex partner, % 11 8 0.53 9 4 0.69
Median no. years in sex work (IQR) 2.5 (6.5) 4.0 (3) 0.48 4 (5) 4 (3) 0.94
History of forced sex 44 37 0.73 39 37 0.87
Lifetime HIV testing history, %:
Never tested 22 52 48 50
Once 44 30 0.01 13 34 0.02
Twice 0 14 17 12
3–5 times 22 5 17 3
$6 times 11 1 5 1
Had HIV test in past 6 months, % 11 2 0.18 4 2 0.42
$1 AIDS symptom in last 6 months
+, % 33 43 0.73 22 19 0.77
Median baseline CD4 cells/ml (IQR) 447 461 0.77 590 444 ,0.01
Classified as RI by baseline STARHS test during cross-
sectional survey, %
100 0 ,0.0001 65 17 ,0.0001
Median no. days between baseline and repeat STARHS test692 623 0.69 593 641 0.42
Abbreviations: RI=recent infection; LTI=long-term infection.
1P-values for the Chi-square or Fisher’s exact tests for categorical variables, and the Wilcoxon-Mann-Whitney test for continuous variables.
+Includes: recent unexpected weight loss, chronic diarrhea, chronic weakness, fever, cough, night sweats, oral candidiasis.
doi:10.1371/journal.pone.0018402.t001
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women in the survey sample who were eligible (i.e., HIV negative)
but did not enroll. Indeed, cohort participants tended to be lower
risk than non-enrolled women (data not shown). In addition,
observation biases such as the Hawthorne effect or study-related
risk-reduction interventions (e.g., condom provision, prevention
counseling, STI treatment) may create artifactual differences in
rates between prospective and cross-sectional samples[1]. We did
observe a non-significant downward trend in incidence in the
prospective cohort during follow-up, which could be due to the
Hawthorne effect and/or some effect of study interventions. While
specific reasons for the downward trend are difficult to isolate, the
trend supports using early (first 6 months) rates from the cohort as
the most appropriate comparator for STARHS-based estimates.
Table 2. HIV incidence estimates based on STARHS assays among ARV-naı ¨ve, high-risk women in Kigali, Rwanda.
Assay
Number HIV
positive
Number
Recent
Number HIV
negative
Assay window
period
1 Estimated Incidence
Unadjusted estimates
BED-CEIA 190 36 610 330 6.5 (3.2, 9.9)
AxSYM Avidity Index 190 56 610 310 10.8 (5.6, 16.0)
BED and Ax-AI 190 23 610 267 5.2 (2.2, 8.1)
CD4-adjusted estimates, cut-off $200 cells/ml
2
BED-CEIA 190 31 610 330 5.6 (2.6, 8.6)
AxSYM Avidity Index 190 50 610 310 9.7 (5.0, 14.4)
BED and Ax-AI 190 21 610 267 4.7 (2.0, 7.5)
Adjusted with local BED false-recent rate of 3.6%
3
BED-CEIA 190 36 610 330 5.5 (2.2, 8.7)
Adjusted with local Ax-AI false-recent rate of 10.6%
3
AxSYM Avidity Index 190 56 610 310 7.7 (3.2, 12.3)
Adjusted with local BED/Ax-AI combined false-recent rate of 2.1%
3
BED and Ax-AI 190 23 610 267 4.4 (1.4, 7.3)
1. Sample-specific window periods, based on data from seroconverter panel.
2. CD4 adjustment removes individuals with CD4,200 from recent infection classifications: 2 from Concordant; 5 from BED-RI.
3. False-recent rate calculations exclude individuals taking antiretroviral therapy and with CD4 count ,200 cells/ml. Assuming a CoV for the window period of 20%; (CoV
for FRR were calculated and input into spreadsheet).
doi:10.1371/journal.pone.0018402.t002
Figure 3. STARHS assay-based incidence estimates, cross-sectional sample.
doi:10.1371/journal.pone.0018402.g003
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reported for Zimbabwean[9] and North American[8] samples, but
was higher than the rate reported for a rural South African
sample[18]. Compositional, clinical (e.g., circulating HIV subtype
or ART coverage), or biologic differences (e.g., disease progres-
sion) among the study populations could explain differences in the
FRR. To our knowledge, this is the first publication of a false-
recent rate for the Ax-AI method based on follow-up STARHS
testing of HIV-positive survey participants. In this study, the FRR
of the Ax-AI method was higher than the FRR for the BED assay.
Although few studies have compared and contrasted results from
the two assays, one study in Co ˆte d’Ivoire did report poorer
specificity on the Ax-AI as compared to the BED in prospective
study seroconverter panels[7]. Poorer performance of the Ax-AI in
this study, including the low correlation with BED, could be due to
suboptimal cross-reactivity with a range of HIV-1 subtypes[24].
Estimated mean window periods for the BED and Ax-AI assays
among participants in the prospective sample were substantially
longer than published window period values (330 vs. 155 days for
BED, and 310 vs. 180 days for Ax-AI). Differences in mean
window period may reflect underlying variability in the biologic
response after infection with different HIV-1 subtypes[10,25].
Indeed, a recent analysis of data from multiple HIV seroconver-
sion cohorts with varying HIV subtypes estimated the overall
mean BED window period to be 197 days, with longer window
periods for African vs. non-African cohorts (Parekh et al.,
submitted). While the small sample size and lack of robust methods
led to a high degree of uncertainty in our sample-specific window
period estimates, they suggest potential improvement in assay
performance with longer window periods—a finding that
underscores the benefit of using a locally derived window period.
For example, using the manufacturer’s window period of 155 days
for BED, the unadjusted incidence estimate is 13.9/100 PY (95%
CI: 6.7–21.0), versus 6.5/100 PY (3.2, 9.9) with our estimated
local window period of 330 days. An ideal assay would be
applicable to all HIV-1 subtypes, as well as not rely on modifying
existing commercial assays, be easy to transfer in the field, and be
unaffected by changes in HIV antigen-specific antibodies associ-
ated with long-term infection.
This is also the first report of a false-recent rate for the
combined BED/Ax-AI algorithm. The FRR for the combined
BED/Ax-AI algorithm (among ART-naı ¨ve participants) was lower
than the individual assay FRR, at only 2.1%. Indeed sequential
testing with two STARHS assays is increasingly being recom-
mended as a strategy for reducing misclassification and improving
incidence estimates[26,27]. However, with two assays that perform
sub-optimally in a given population there will be a trade-off
between improved specificity and loss of sensitivity[8]. Availability
of ART has rapidly increased in Rwanda during the past few
years[28]. As individuals taking ART may be misclassified on
STARHS assays because of changes in HIV antibody level due to
treatment, misclassification rates in this population may increase
over time as more individuals initiate treatment[18]. The ART
status of survey participants, especially those testing recent on
assays, should be measured systematically (e.g., therapeutic drug
monitoring (TDM), chart review, self-report) so that individuals
taking ART can be excluded from incidence analyses and FRR
calculations[29].
Several factors were associated with testing false-recent on the
assays among HIV-positive participants with known LTI,
including having been classified as RI by the assays at baseline;
more frequent history of HIV testing; and older age (borderline
significant association). HIV testing history and older age were
significantly positively associated with long-term HIV infection in
this sample (data not shown). The association between testing
false-recent and having a prior STARHS classification of RI may
reflect the presence of ‘‘assay non-progressors’’ in this sample, or
individuals who are repeatedly classified as RI by STARHS assays
over time because of sustained low antibody levels[26]. Further,
false-recent classification by Ax-AI could be due, in part, to
infection with multiple HIV clades, wherein subsequent waves of
antibody production maintain low antibody avidity[30–32]. Our
observation of a higher Ax-AI-false recent rate among participants
with an HIV-positive partner, frequent HIV testing history, and
higher baseline CD4 count, support such a hypothesis.
In this population, adjustment of STARHS-based incidence
estimates with FRR brought estimates closer to the gold standard
estimated cohort incidence rate than did adjustment using a CD4
cutoff of ,200 CD4 cells/ml for probable LTI. Incidence surveys
should use a locally derived, population-specific FRR versus a
published rate from a different population, and indeed should be
reconsidered when a local FRR is not available. While follow-up of
a long-term infection cohort such as was done in this study is the
optimal method for estimating an FRR, false-recent rates can also
be estimated in sufficiently large cross-sectional samples of ART-
naı ¨ve individuals with long-term infection. In our study, CD4
adjustment also appeared to help reduce potential inflation of
estimates, which underscores the value of CD4 data for adjusting
and interpreting STARHS results, and thus the importance of
incorporating CD4 count measurement into national or popula-
tion-based serosurveys using STARHS to estimate HIV incidence
if feasible. CD4 testing may be feasible, for example, in settings
with enhanced clinical and laboratory capacity as a result of
treatment scale-up. Ideally, assay FRR and CD4 count data, along
with other clinical information, would be available for adjusting
STARHS-based incidence estimates.
This study has several strengths. The combined cross-sectional
and prospective design enabled us to compare incidence estimates,
derive population-specific FRR on the assays, including for the
combined test algorithm, and estimate assay window periods from
serial specimens from individuals with known interval of HIV
seroconversion. The use of two STARHS assays contributes
important information about the assays’ independent and relative
performance in a high-risk setting with little experience with
STARHS. Discussion is ongoing regarding the optimal assay
parameters (e.g., window periods, cutoff values, including use of a
‘‘grey zone’’ instead of a single value) for a combined BED/Ax-AI
algorithm.
Study limitations are also noted. The small sample size of the
study, and relatively few HIV seroconversions and recent infection
classifications, may have limited statistical power for certain
analyses. Specifically, the small sample size, along with other study
design features, prohibited the use of more robust statistical
methods for comparing the cross-sectional and prospective
incidence rates, such as equivalence tests[33], and may have also
led to reduced precision around the assay FRR estimates[9].
However, the statistical approach employed for incidence
estimation does attempt to quantify the affect of uncertainty in
the calibrating parameters (e.g., FRR and window period) on the
incidence estimates. Furthermore, our approach to CD4-adjust-
ment of STARHS classifications (using a cutoff of ,200ml for LTI)
may have erroneously excluded individuals with primary HIV
infection and low CD4 count[34] from the RI classification.
However, the lower limit of 287 CD4 cells/ml among recent
seroconverters in this sample suggests that using a cutoff of
CD4,200 for adjustment would not result in the loss of many
individuals with true RI status in incidence estimates (indeed there
were no individuals with CD4,50 and RI status on the assays).
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rather than by pharmacokinetic testing. However, women in the
baseline survey were newly diagnosed with HIV by the study and
so were assumed to be ART-naı ¨ve, and even at follow-up few
women would have begun taking ART given the relatively short
time since diagnosis. Finally, although some studies have shown
that the Ax-AI method may be more specific than the BED
assay[35,36], the ideal dual testing algorithm would include a
confirmatory test with perfect specificity.
In this sample of Rwandan FSW, adjusted incidence estimates
based on a combined BED/Ax-AI algorithm were similar to the
estimated HIV incidence rate in the first 6 months of cohort
follow-up, when incidence was highest. Furthermore, false-recent
rate on the combined BED/Ax-AI algorithm was low, and
substantially lower than for either assay alone. In population-based
testing, specificity of the BED and Ax-AI assays, and the combined
test algorithm, would be expected to be substantially higher given
that a larger proportion of individuals will have longer-term HIV
infection.
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